Tyrosine kinase inhibitors (TKIs) have demonstrated enhanced efficacy and reduced toxicity in EGFR-sensitive patients compared to classical chemotherapy treatments because of their ability to target specific molecular abnormalities associated with NSCLC cells [8–13]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.